![Study design and flow. The design is an assessor-blind, parallel group,... | Download Scientific Diagram Study design and flow. The design is an assessor-blind, parallel group,... | Download Scientific Diagram](https://www.researchgate.net/publication/324035255/figure/fig1/AS:643257214193664@1530375879011/Study-design-and-flow-The-design-is-an-assessor-blind-parallel-group-randomized.png)
Study design and flow. The design is an assessor-blind, parallel group,... | Download Scientific Diagram
![Effects of two types of exercise training on psychological well-being, sleep, quality of life and physical fitness in patients with high-grade glioma (WHO III and IV): study protocol for a randomized controlled Effects of two types of exercise training on psychological well-being, sleep, quality of life and physical fitness in patients with high-grade glioma (WHO III and IV): study protocol for a randomized controlled](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40880-019-0390-8/MediaObjects/40880_2019_390_Fig1_HTML.png)
Effects of two types of exercise training on psychological well-being, sleep, quality of life and physical fitness in patients with high-grade glioma (WHO III and IV): study protocol for a randomized controlled
![Active placebo control group controls for the normal placebo benefits... | Download Scientific Diagram Active placebo control group controls for the normal placebo benefits... | Download Scientific Diagram](https://www.researchgate.net/profile/Erik-Peper/publication/321711955/figure/fig2/AS:569831491465216@1512869822980/Active-placebo-control-group-controls-for-the-normal-placebo-benefits-plus-those-placebo_Q320.jpg)
Active placebo control group controls for the normal placebo benefits... | Download Scientific Diagram
![Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design](https://scielo.isciii.es/img/revistas/ejpen/v30n1/original02_figura5.jpg)
Clinical trial designs of new medicinal products for treating schizophrenia: discussion of EMA's Guideline and a Better Long Term Trial Design
![Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial ... Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial ...](https://www.thelancet.com/cms/attachment/5642aa5a-0bd9-42ef-bb2b-fd2662859752/gr1.gif)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial ...
![An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial | JACC: Clinical Electrophysiology An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial | JACC: Clinical Electrophysiology](https://www.jacc.org/cms/asset/b1ae7625-5846-459b-ad78-3f915314b0c0/fx1.jpg)
An Exercise and Physical Activity Program in Patients With Atrial Fibrillation: The ACTIVE-AF Randomized Controlled Trial | JACC: Clinical Electrophysiology
![Review the Efficacy and Safety of LYBALVI® (olanzapine and samidorphan) from ENLIGHTEN-1 | Official Website for Healthcare Professionals Review the Efficacy and Safety of LYBALVI® (olanzapine and samidorphan) from ENLIGHTEN-1 | Official Website for Healthcare Professionals](https://www.lybalvihcp.com/Content/images/content-images/study-design-enlighten-1-pivotal-study.png)
Review the Efficacy and Safety of LYBALVI® (olanzapine and samidorphan) from ENLIGHTEN-1 | Official Website for Healthcare Professionals
![Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - The Lancet Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/646e3166-1a7d-439f-b578-50f91d46b4b3/gr1.jpg)
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - The Lancet
![A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance - European Urology Focus A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/asset/d523c220-54c3-4ef3-ab0e-28bcadb8ad28/gr1.jpg)
A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance - European Urology Focus
![Study design of active-controlled non-inferiority trial of ivabradine... | Download Scientific Diagram Study design of active-controlled non-inferiority trial of ivabradine... | Download Scientific Diagram](https://www.researchgate.net/publication/285842487/figure/fig4/AS:670496966316044@1536870342629/Study-design-of-active-controlled-non-inferiority-trial-of-ivabradine-versus-amlodipine.png)
Study design of active-controlled non-inferiority trial of ivabradine... | Download Scientific Diagram
![The Pervasive Problem With Placebos in Psychology: Why Active Control Groups Are Not Sufficient to Rule Out Placebo Effects - Walter R. Boot, Daniel J. Simons, Cary Stothart, Cassie Stutts, 2013 The Pervasive Problem With Placebos in Psychology: Why Active Control Groups Are Not Sufficient to Rule Out Placebo Effects - Walter R. Boot, Daniel J. Simons, Cary Stothart, Cassie Stutts, 2013](https://journals.sagepub.com/cms/10.1177/1745691613491271/asset/images/large/10.1177_1745691613491271-fig1.jpeg)